Bright Minds Biosciences Inc. DRUG R2KR3KPHARMA
Company Overview
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.02.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +29.44% |
| 6 Months: | -41.14% |
| 3 Months: | -27.02% |
| 1 Month: | -1.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DRUG Bright Minds Biosciences Inc. R2KR3KPHARMA | 52.48 | -25.73 | $514.94M | 0.00% | -16.98% | -13.63% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 3.35M | 3.30M | 5.66M | 6.90M | 15.32M |
| Operating Income | - | -3.35M | -3.30M | -5.66M | -6.90M | -15.32M |
| EBITDA | - | -3.33M | -3.28M | -5.65M | -6.88M | -15.30M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -2.95M | -5.24M | -4.09M | -7.57M | -10.46M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -2.95M | -5.24M | -4.09M | -7.57M | -10.46M |
| Diluted EPS | 0.01 | -0.42 | -0.74 | - | -0.97 | -1.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 14.98M | 7.39M | 2.82M | 13.94M |
| Operating Income | - | -14.98M | -7.39M | -2.82M | -13.94M |
| EBITDA | - | -14.97M | -7.31M | -2.75M | -13.86M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -14.96M | -7.37M | -2.80M | -12.23M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -14.96M | -7.37M | -2.80M | -12.23M |
| Diluted EPS | - | -6.06 | -1.98 | -0.65 | -1.78 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 12.09M | 6.88M | 6.10M | 84.42M |
| Current Assets | - | 11.95M | 6.81M | 5.99M | 84.31M |
| Cash & Equivalents | - | 11.63M | 6.75M | 5.72M | 82.91M |
| Inventory | - | - | - | - | - |
| Receivables | - | 155.78K | 36.98K | 50.22K | 413.07K |
| Total Liabilities | - | 1.54M | 280.86K | 568.26K | 2.38M |
| Current Liabilities | - | 1.47M | 280.86K | 528.68K | 2.34M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 139.91K | 73.55K | 118.96K | 125.78K |
| Total Equity | - | 10.54M | 6.60M | 5.54M | 82.04M |
| Shares Outstanding | - | 3.52M | 3.77M | 4.52M | 7.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -13.59M | -7.02M | -1.85M | -8.69M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | 5.20M | 2.19M | 810.57K | 85.57M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -13.59M | -7.02M | -1.85M | -8.69M |
| Net Change in Cash | - | -8.39M | -4.83M | -1.04M | 76.88M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -141.9% | -111.7% | -50.6% | -14.9% |
| ROCE % | - | -141.1% | -111.9% | -50.6% | -17.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 13.86% | 1.35M | $72.92M |
| 2 | Cormorant Asset Management, LP | 9.25% | 900.00K | $48.64M |
| 3 | Blackrock Inc. | 7.05% | 686.18K | $37.09M |
| 4 | Vivo Capital, LLC | 5.73% | 557.17K | $30.12M |
| 5 | Vestal Point Capital, LP | 5.60% | 545.00K | $29.46M |
| 6 | Braidwell LP | 4.97% | 483.82K | $26.15M |
| 7 | Driehaus Capital Management, LLC | 4.45% | 433.38K | $23.42M |
| 8 | Balyasny Asset Management LP | 3.55% | 345.05K | $18.65M |
| 9 | Adage Capital Partners GP L.L.C. | 3.44% | 335.00K | $18.11M |
| 10 | Point72 Asset Management, L.P. | 3.36% | 327.42K | $17.70M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DRUG
Bright Minds Biosciences Inc. (DRUG.CN) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5XZTVweEVQMnFJNXZReDhDendnZXBFODZLMVVFZGpSSWIxdlJqVEJxM3RQZUZxYTQtcEd4c0FkOHVacExyYWdla2JzM2VRWnBNX3hhR0tR?oc=5" target="_blank">Bright Minds Biosciences Inc. (DRUG.CN) Stock Price…
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxOMlRMM0NlUG15Q0NQX1g1MFJZLVVfeEpvYlN4X09pOUpLV1NydDI0SmZDMzBINVRzbUctVWJCMjl1eE55ODVIY1h6YzFfR1BkNnZsQUVqaFQzLVhVQ29VRUF4eWdlZ2F2cHB6eWRGZHZZeHdlTzQya0hELURTc3V6LVRkZ3ptN3czb3RSYj…
Cumberland sees stock skyrocket as drug update nears - Nashville Post
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMVNqZ1FxeFo5R0VtbnQxcHlpcmk0RHpZN2pWMDZ1YWNpOGEyTXJ3VHhUZy1NQXBmbGlqUHo4UGdYSzFuRTI0eWdKc2RhS1RPc3NaSURXN0VVdXdPU3pTb0t3LVpYM043SzRhN0p2dDhqclZOQW80ckh5NzJNYTdSaW1YZ0dBU0RIMm9Xc0…
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock? - Trefis
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSlhrU0l1WHVCTjN5cUlNOEFFWHAydmFDM3RNQmcwOExBVm83U1RRUFUwWEhoRGFzNkZjTGRmNTJfVkZ6VUY0ZVVtSnhlcFU3RXlrejREUHNCOVEtQzRweTE5RE5BN2JwZXlnVFZodVhzSjJSM2ZuN2hFeENOaTVYd09lTjVvT090YVNESW…
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQYWlDVFZOengzV3gxc2xmYWJsTXJMazhzVk9HRXRjbnU5bTlTVXg4Q2tEdERxSXZBQUloeTVvVnpISTBYOXVSNjVEN0dOcTV1YjdNNG5vd1djbExya2wtYlM4VmlQVldTbmpGSUhBNUhSVGJUVFEtd0hqMTNnS3NjQmZUUXFJQXEzUU4wb2…
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNT211R1VFOXNzeURPLUdFWXA4QVhTT1hhR1ZNQm0tVkJyMVVWbmpadW82WkZUbWo2ZlI0bFZ3UmxGZG84cUpYbkItWDlZaWVNdjRTaFF0RHg2eHBPYjhCakZVMDNNWE9UdEkxeVEtNG5jM2wyZVMyNXVXZjc2Vm9YZWFIdmlhZDJfRjRuSV…
DRUG — Frequently Asked Questions
What is the current share price of Bright Minds Biosciences Inc. (DRUG)?
As of 2026-10-23 16:27 PDT, Bright Minds Biosciences Inc. (DRUG) trades at $52.48 on NasdaqCM. Its 52-week range is $38.80 to $95.98.
What is the market capitalisation of DRUG?
Bright Minds Biosciences Inc. (DRUG) has a market capitalisation of $514.94M on NasdaqCM.
What is the P/E ratio of DRUG?
DRUG trades at a trailing price-to-earnings (P/E) ratio of -25.73. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.73.
What is the return on equity (ROE) of DRUG?
DRUG has a return on equity (ROE) of -13.63%. Its return on capital employed (ROCE) is -16.98%.
Is DRUG a good stock to buy?
This page provides a data-driven analysis of Bright Minds Biosciences Inc. (DRUG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.